Practical and conceptual challenges in measuring antiretroviral adherence

被引:230
作者
Berg, Karina M. [1 ]
Arnsten, Julia H. [1 ]
机构
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Gen Internal Med, Bronx, NY 10467 USA
关键词
adherence; antiretroviral; HIV; measurement; research methods;
D O I
10.1097/01.qai.0000248337.97814.66
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Accurate measurement of antiretroviral adherence is essential for targeting and rigorously evaluating interventions to improve adherence and prevent viral resistance. Across diseases, medication adherence is an individual, complex, and dynamic human behavior that presents unique measurement challenges. Measurement of medication adherence is further complicated by the diversity of available measures, which have different utility in clinical and research settings. Limited understanding of how to optimize existing adherence measures has hindered progress in adherence research in HIV and other diseases. Although self-report is the most widely used adherence measure and the most promising for use in clinical care and resource-limited settings, adherence researchers have yet to develop evidence-based standards for self-reported adherence. In addition, the use of objective measures, such as electronic drug monitoring or pill counts, is limited by poor understanding of the source and magnitude of error biasing these measures. To address these limitations, research is needed to evaluate methods of combining information from different measures. The goals of this review are to describe the state of the science of adherence measurement, to discuss the advantages and disadvantages of common adherence measurement methods, and to recommend directions for improving antiretroviral adherence measurement in research and clinical care.
引用
收藏
页码:S79 / S87
页数:9
相关论文
共 95 条
  • [1] Position paper on therapeutic drug monitoring of antiretroviral agents
    Acosta, EP
    Gerber, JG
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) : 825 - 834
  • [2] *AIDS I NEW YORK S, PROM ADH HIV ANT THE
  • [3] Assessment of adherence to triple antiretroviral treatment including indinavir: Role of the determination of plasma levels of indinavir
    Alcoba, M
    Cuevas, TJ
    Perez-Simon, MR
    Mostaza, TL
    Ortega, L
    de Urbina, JO
    Carro, JA
    Raya, T
    Abad, M
    Martin, V
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (02) : 253 - 258
  • [4] Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease
    Alexander, CS
    Asselin, JJ
    Ting, LSL
    Montaner, JSG
    Hogg, RS
    Yip, B
    O'Shaughnessy, MV
    Harrigan, PR
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (04) : 541 - 548
  • [5] Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
  • [6] [Anonymous], 2001, AIDS and Behavior
  • [7] Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring
    Arnsten, JH
    Demas, PA
    Farzadegan, H
    Grant, RW
    Gourevitch, MN
    Chang, CJ
    Buono, D
    Eckholdt, H
    Howard, AA
    Schoenbaum, EE
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) : 1417 - 1423
  • [8] Therapeutic drug monitoring in HIV infection: current status and future directions
    Back, D
    Gatti, G
    Fletcher, C
    Garaffo, R
    Haubrich, R
    Hoetelmans, R
    Kurowski, M
    Luber, A
    Merry, C
    Perno, CF
    [J]. AIDS, 2002, 16 : S5 - S37
  • [9] Bangsberg D.R., 2001, AIDS Behav, V5, P275, DOI [10.1023/A:1011396711486, DOI 10.1023/A:1011396711486]
  • [10] Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    Bangsberg, DR
    Hecht, FM
    Charlebois, ED
    Zolopa, AR
    Holodniy, M
    Sheiner, L
    Bamberger, JD
    Chesney, MA
    Moss, A
    [J]. AIDS, 2000, 14 (04) : 357 - 366